Journal
BLOOD CELLS MOLECULES AND DISEASES
Volume 45, Issue 2, Pages 117-123Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bcmd.2010.05.007
Keywords
Runx; Haematopoietic; Mammary; Prostate; Oncogene
Categories
Funding
- NIH Office of Rare Diseases
- Company of Biologists
- MRC Molecular Haematology Unit
- Leukaemia Research Fund
- Heinrich Pette Institut
- Association for International Cancer Research
- Cancer Research UK
- Leukaemia and Lymphoma Research
Ask authors/readers for more resources
The Runx transcription factors are essential for mammalian development, most notably in the haematopoietic and osteogenic lineages. Runx1 and its binding partner, CBF beta,, are frequently targeted in acute leukaemia but evidence is accumulating that all three Runx genes may have a role to play in a wider range of cancers, either as tumour promoters or tumour suppressors. Whilst Runx2 is renowned for its role as a master regulator of bone development we discuss here its expression pattern and putative functions beyond this lineage. Furthermore, we review the evidence that RUNX2 promotes neoplastic development in haematopoietic lineages and in advanced mammary and prostate cancer. (C) 2010 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
